Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 9/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927112 | 0.88 | CHRM1 (0.60) | CHRM1ALDH1A1PKMHTTNPSR1 | |
| SCHEMBL30202003 | 0.88 | CHRM1 (0.60) | CHRM1ALDH1A1PKMHTTNPSR1 | |
| SCHEMBL23927191 | 0.86 | LMNA (0.47) | LMNANOTUM | |
| SCHEMBL23927186 | 0.85 | CHRM1 (0.43) | CHRM1ALDH1A1PKMHTTNPSR1 | |
| SCHEMBL23927146 | 0.85 | CHRM1 (0.51) | CHRM1ALDH1A1PKMHTTNPSR1 | |
| SCHEMBL23881519 | 0.83 | CHRM1 (0.49) | CHRM1ALDH1A1PKMHTTNPSR1 | |
| SCHEMBL23927116 | 0.83 | CHRM1 (0.49) | CHRM1ALDH1A1PKMHTTNPSR1 | |
| SCHEMBL30202084 | 0.83 | CHRM1 (0.49) | CHRM1ALDH1A1PKMHTTNPSR1 | |
| SCHEMBL23927190 | 0.83 | CHRM1 (0.49) | CHRM1ALDH1A1PKMHTTNPSR1 | |
| SCHEMBL23927158 | 0.80 | CHRM1 (0.50) | CHRM1ALDH1A1PKMHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287082-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2024-08-29 | — | — | US | disclosed |
| EP-4405043-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| CN-118043326-A | Benzodiazepine derivatives as GABAA γ1 PAM | 豪夫迈·罗氏有限公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-4139310-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2023046817-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2023-03-30 | — | — | WO | disclosed |
| EP-4139310-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| WO-2021213952-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2021-10-28 | — | — | WO | disclosed |
| EP-3901155-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287082-A1 | NEW BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | GABRA1, GABRB1, GABRA5 | CHRM1 41/4885ALDH1A1 571/4885PKM 487/4885 |
| US-20230141603-A1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | GABRA1, GABRB1, GABRB3 | CHRM1 58/4885ALDH1A1 600/4885PKM 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.